Staggering Results Show HIV-Transmission Reduced 100% with Twice-Yearly Lenacapavir Injection
A new HIV-prevention drug, Lenacapavir, administered twice yearly via injection, showed 100% efficacy in preventing HIV transmission in a trial involving 3,200 participants in high-HIV-incidence regions like Uganda and South Africa. A follow-up trial with 5,000 participants across multiple countries and age groups achieved a 99.9% reduction in infection rates. These results suggest the drug could be a highly effective tool in preventing HIV transmission globally.
A new HIV-prevention drug, Lenacapavir, given twice a year as an injection, prevented all HIV infections in a trial with 3,200 people in high-HIV-incidence countries.
This breakthrough could dramatically reduce new HIV infections worldwide by offering a long-acting, highly effective prevention method that is easier to use than daily pills.
This news highlights a major step forward in global health, showing how medical innovation can empower people to protect themselves and reduce the spread of HIV.
upbeatBytes summarizes in its own words and links to the original publisher — it doesn't host the article.